Montanaro Asset Management Ltd Buys 13,640 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• Montanaro Asset Management Ltd increased its stake in TransMedics Group by 9.7%, holding 153,675 shares, making it the 14th largest holding in their portfolio.
• Insiders at TransMedics Group, including director Anil P. Ranganath, sold shares recently, with Ranganath's transaction resulting in a 4.69% decrease in his ownership.
• TransMedics Group reported an earnings per share (EPS) of $0.92, significantly beating analysts' expectations and showing a 37.7% revenue increase year-over-year.

Montanaro Asset Management Ltd lifted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 9.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 153,675 shares of the company's stock after acquiring an additional 13,640 shares during the quarter. TransMedics Group makes up 3.0% of Montanaro Asset Management Ltd's portfolio, making the stock its 14th biggest holding. Montanaro Asset Management Ltd owned 0.45% of TransMedics Group worth $10,339,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. OneDigital Investment Advisors LLC increased its stake in shares of TransMedics Group by 52.6% in the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock worth $403,000 after acquiring an additional 2,065 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of TransMedics Group by 2.8% in the first quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock worth $13,350,000 after acquiring an additional 5,480 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in shares of TransMedics Group in the first quarter worth $291,000. New York State Teachers Retirement System increased its stake in shares of TransMedics Group by 183.2% in the first quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock worth $1,477,000 after acquiring an additional 14,200 shares during the last quarter. Finally, Sugar Maple Asset Management LLC acquired a new position in TransMedics Group during the first quarter worth $740,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

TMDX stock traded down $2.30 during mid-day trading on Thursday, reaching $129.74. 875,947 shares of the stock traded hands, compared to its average volume of 1,392,768. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The business has a 50-day moving average of $123.89 and a two-hundred day moving average of $99.05. The firm has a market capitalization of $4.42 billion, a PE ratio of 67.22 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period in the prior year, the company earned $0.35 earnings per share. The business's quarterly revenue was up 37.7% compared to the same quarter last year. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director owned 2,866 shares of the company's stock, valued at approximately $362,405.70. The trade was a 63.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,418 shares of company stock worth $818,833 over the last ninety days. Company insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

TMDX has been the topic of several analyst reports. Oppenheimer increased their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Piper Sandler reissued an "overweight" rating and set a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $123.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.